Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rounded incidence values (%) of renal and nonrenal events

Published byΜαρία Βασιλικός Modified over 6 years ago

Similar presentations

Presentation on theme: "Rounded incidence values (%) of renal and nonrenal events"— Presentation transcript:

1 Rounded incidence values (%) of renal and nonrenal events
Control Aminocaproic acid Tranexamic acid Aprotinin p Renal dialysis 1 5 <0.001 Renal dysfunction 2 3 Composite renal outcome 4 8 Death 0.004 Composite outcome 19 20 21 29 CV event 16 17 22 MI 13 12 <0.005 CHF 6 9 Stroke 0.08 Encephalopathy Composite renal outcome=renal dysfunction or renal failure requiring dialysis Composite outcome event=death, renal event, cardiovascular event, or cerebrovascular event Mangano DT et al. N Engl J Med 2006; 354:

Download ppt "Rounded incidence values (%) of renal and nonrenal events"

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.

V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
STROKE STATS Third leading cause of death 160 000 deaths a year 731 000 strokes a year 4 400 000 stroke survivors Leading cause of adult disability Source:

STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source:
Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents
Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.

Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.
1 Combined CRD and DSaRM Advisory Committee Meeting Trasylol (aprotinin) NDA 20-304 Overview George Shashaty, M.D. Division of Medical Imaging and Hematology.

1 Combined CRD and DSaRM Advisory Committee Meeting Trasylol (aprotinin) NDA Overview George Shashaty, M.D. Division of Medical Imaging and Hematology.
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
CRDAC & DSaRM Advisory Meeting September 12, 2007 Aprotinin Observational Studies Advisory Committee Meeting - September 12, 2007 Rita Ouellet-Hellstrom,

CRDAC & DSaRM Advisory Meeting September 12, 2007 Aprotinin Observational Studies Advisory Committee Meeting - September 12, 2007 Rita Ouellet-Hellstrom,
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Similar presentations

Ads by Google